We’re excited to partner with Comprehensive Cell Solutions (CCS), a division of New York Blood Center, to conduct a comparative assessment of ZipThaw versus traditional thawers.

We’ll focus on evaluating cryopreserved cell therapy starting material (apheresis) — thawing consistency is key for downstream performance.

By enhancing thaw performance early in the process, our goal is to increase manufacturing efficiency and ensure consistently high-quality products.

Together, we’re committed to advancing technologies that strengthen the journey from starting material to patients who rely on life-changing cell therapies.